Gopi Hosahudya, Umashankara M, Pirrone Vanessa, LaLonde Judith, Madani Navid, Tuzer Ferit, Baxter Sabine, Zentner Isaac, Cocklin Simon, Jawanda Navneet, Miller Shendra R, Schön Arne, Klein Jeffrey C, Freire Ernesto, Krebs Fred C, Smith Amos B, Sodroski Joseph, Chaiken Irwin
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, USA.
J Med Chem. 2008 May 8;51(9):2638-47. doi: 10.1021/jm070814r. Epub 2008 Apr 11.
Structure-activity correlations were investigated for substituted peptide conjugates that function as dual receptor site antagonists of HIV-1 gp120. A series of peptide conjugates were constructed via click reaction of both aryl and alkyl acetylenes with an internally incorporated azidoproline 6 derived from the parent peptide 1 (12p1, RINNIPWSEAMM). Compared to 1, many of these conjugates were found to exhibit several orders of magnitude increase in both affinity for HIV-1 gp120 and inhibition potencies at both the CD4 and coreceptor binding sites of gp120. We sought to determine structural factors in the added triazole grouping responsible for the increased binding affinity and antiviral activity of the dual inhibitor conjugates. We measured peptide conjugate potencies in both kinetic and cell infection assays. High affinity was sterically specific, being exhibited by the cis- but not the trans-triazole. The results demonstrate that aromatic, hydrophobic, and steric features in the residue 6 side-chain are important for increased affinity and inhibition. Optimizing these features provides a basis for developing gp120 dual inhibitors into peptidomimetic and increasingly smaller molecular weight entry antagonist leads.
对作为HIV-1 gp120双受体位点拮抗剂的取代肽缀合物进行了构效关系研究。通过芳基和烷基乙炔与源自亲本肽1(12p1,RINNIPWSEAMM)的内部掺入的叠氮基脯氨酸6的点击反应构建了一系列肽缀合物。与1相比,发现许多这些缀合物对HIV-1 gp120的亲和力以及在gp120的CD4和共受体结合位点的抑制效力均提高了几个数量级。我们试图确定添加的三唑基团中导致双抑制剂缀合物结合亲和力和抗病毒活性增加的结构因素。我们在动力学和细胞感染试验中测量了肽缀合物的效力。高亲和力具有空间特异性,由顺式三唑而非反式三唑表现出来。结果表明,残基6侧链中的芳香、疏水和空间特征对于增加亲和力和抑制作用很重要。优化这些特征为将gp120双抑制剂开发成拟肽和分子量越来越小的进入拮抗剂先导物提供了基础。